Similar Items: Pharmacokinetic analysis of nacubactam, a novel β-lactamase inhibitor, co-administered with meropenem in patients with a complicated urinary tract infection
- In vitro activity of the novel β-lactamase inhibitor nacubactam against a nationwide collection of carbapenem-resistant Enterobacterales in Japan
- Update on the comparative in vitro activity of cefiderocol and four β-lactam–β-lactamase-inhibitor combinations against clinically important Gram-negative pathogens
- Bacteremic versus Non-Bacteremic Urinary Tract Infections: Predictors of Poor Clinical Outcome
- Therapeutic strategies for multi-resistant Escherichia coli in urinary tract infections—a cause for concern
- Correction to: Therapeutic strategies for multi-resistant Escherichia coli in urinary tract infections—a cause for concern
- Carbapenem resistance in community-acquired urinary tract infections caused by Klebsiella pneumoniae and Escherichia coli in Morocco: a multicentre study (January 2022–December 2023)‘Carbapenem resistance in community UTIs in Morocco’